Table 2 Clinicopathologic characteristic
Characteristic | Number (%) | Characteristic | Number (%) |
|---|---|---|---|
Age (years) | RT modality | ||
Median (range) | 60 (39–85) | RT alone | 55 (39%) |
< 60 | 72 (5.1) | concurrent CRT | 47 (33.3%) |
≥ 60 | 69 (48.9) | sequential CRT | 39 (27.7%) |
Gender | Tumor stage | ||
Male | 97 (68.8%) | T1 | 26 (18.4%) |
Female | 44 (31.2%) | T2 | 46 (32.6%) |
KPS (70–100) | T3 | 38 (27%) | |
70–80 | 5 (3.5%) | T4 | 31 (22%) |
80–90 | 28 (19.9%) | Lymph nodes stage | |
90–100 | 108 (76.6) | N0 | 42(29.8%) |
Smoking | N1 | 48 (34%) | |
No | 68 (48.2%) | N2 | 32 (22.7%) |
Yes | 73 (51.8%) | N3 | 19 (13.5%) |
Weight loss (%) | Clinical stage | ||
Median (range) | 3 (0–10) | I | 5 (3.5%) |
≤ 3% | 72 (51.1) | II | 47 (33.3%) |
> 3%-10% | 69 (48.9) | IIIA | 62 (44%) |
COPD | IIIB | 27 (19.1%) | |
No | 130 (92.2%) | PA invasion grade | |
Yes | 11 (7.8%) | Grade 0 | 49(34.8%) |
CVD | Grade 1 | 36(25.5%) | |
No | 108 (76.6%) | Grade 2 | 37(26.2%) |
Yes | 33 (23.4%) | Grade 3 | 19(13.5%) |
Hypertension | Target volume (cc) median (range) | ||
No | 109 (77.3%) | ||
Yes | 32 (22.7%) | GTV | 43.6 (9–400.9) |
CCI | CTV | 92.2 (12.56–843.6) | |
Median (range) | 3 (0–7) | PTV | 213.7 (23.5–1025.5) |
< 3 | 62 (44.0%) | D95 to targets (Gy) median (range) | |
≥ 3 | 79 (56.0%) | ||
Tumor location | D95 to GTV | 64.9 (48.1–74.0) | |
Central | 116 (82.3%) | D95 to CTV | 63.1 (46.4–71.9) |
Peripheral | 25 (17.7%) | D95 to PTV | 60.1 (45.6–69.9) |
Pathology | Dmax to PA (Gy) | ||
Adenocarcinoma | 71 (50.3%) | Median (range) | 65.8 (0.6–76.2) |
Squamous | 61 (43.3%) | Dmean to PA (Gy) | |
Large-cell & NOS | 9 (6.4%) | Median (range) | 37.9 (0–71.3) |
RT technique | Dmax to Heart (Gy) | ||
IMRT | 52 (36.9%) | Median (range) | 56 (0.2–65.7) |
3DCRT | 89 (63.1%) | Dmean to Heart (Gy) | |
RT dose (Gy) | Median (range) | 5.2 (0–34.9) | |
Median (range) | 66 (60–76) | ||
< 66 | 62 (44.0%) | ||
≥ 66 | 79 (56.0%) |